Regulatory
What should pharma companies learn from the pandemic? Volume 2
Accelerated Evolution | The “New Normal” For the Pharma industry, Covid-19 has been a catalyst like no other. Even HIV in the 1980s wasn’t...
Brexit’s Uncertainty Principle
While the minutiae of the possible upcoming permutations for drug supply depending on various Brexit outcomes have been written about elsewhere, less thought has been...
Executive Interims: A creative talent solution for medtech
After attending two recent medtech industry meetings, I was struck by the scale of the two opposing forces that the sector is currently experiencing....
Change in regulatory environment and the impact on talent
A view from the TOPRA Summit I approached the first TOPRA Summit in London at the end of May knowing that the world of healthcare...